Clinical Network Systems Limited Filleted accounts for Companies House (small and micro)

COMPANY REGISTRATION NUMBER: 06877536

Clinical Network Systems Limited

Filleted Unaudited Financial Statements

30 April 2026

Clinical Network Systems Limited

Financial Statements

Year ended 30 April 2026

Contents	Page

Statement of financial position	1

Notes to the financial statements	3

Clinical Network Systems Limited

Statement of Financial Position

30 April 2026

	2026		2025
Note	£	£	£

Fixed assets

Tangible assets	5		378,815	368,513

Current assets

Debtors	6	197,820	90,127
Cash at bank and in hand		229,566	13,801
		---------	---------
		427,386	103,928

Creditors: amounts falling due within one year	7	457,768		453,807
		---------		---------
Net current liabilities			30,382	349,879
			---------	---------
Total assets less current liabilities			348,433	18,634

Creditors: amounts falling due after more than one year	8		16,259	21,137

Provisions

Taxation including deferred tax	71,974	10,196
	---------	--------
Net assets/(liabilities)	260,200	( 12,699)
	---------	--------

Capital and reserves

Called up share capital	151,253	150,736
Share premium account	2,119	434
Other reserves	5,825	–
Profit and loss account	101,003	( 163,869)
	---------	---------
Shareholders funds/(deficit)	260,200	( 12,699)
	---------	---------

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.

For the year ending 30 April 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;

- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .

Clinical Network Systems Limited

Statement of Financial Position (continued)

30 April 2026

These financial statements were approved by the board of directors and authorised for issue on 20 August 2026 , and are signed on behalf of the board by:

Mr S M Ogden	Dr J W E Jarman
Director	Director

Company registration number: 06877536

Clinical Network Systems Limited

Notes to the Financial Statements

Year ended 30 April 2026

1. General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is C/O Hierons LLP, 28 Grosvenor Street, (Lg.02), London, W1K 4QR, United Kingdom.

2. Statement of compliance

These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Revenue recognition

Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for services rendered, stated net of discounts and of Value Added Tax. Revenue from services rendered is recognised on a proportional basis relevant to the level of work completed, in accordance with the installation, management and support services provided across contracted periods.

Income tax

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date. Deferred tax is recognised in respect of all timing differences at the reporting date.

Tangible assets

Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Office equipment	-	33% straight line
Software development	-	10% straight line

Impairment of fixed assets

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs.

Provisions

Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event, it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the statement of financial position and the amount of the provision as an expense. Provisions are initially measured at the best estimate of the amount required to settle the obligation at the reporting date and subsequently reviewed at each reporting date and adjusted to reflect the current best estimate of the amount that would be required to settle the obligation. Any adjustments to the amounts previously recognised are recognised in profit or loss unless the provision was originally recognised as part of the cost of an asset. When a provision is measured at the present value of the amount expected to be required to settle the obligation, the unwinding of the discount is recognised as a finance cost in profit or loss in the period it arises.

Financial instruments

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in other administrative expenses. Loans and borrowings are initially recognised at the transaction price including transaction costs. Subsequently, they are measured at amortised cost using the effective interest rate method, less impairment. If an arrangement constitutes a finance transaction it is measured at present value.

Defined contribution plans

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund.

Share-based payments

Equity-settled share-based payment transactions are measured at fair value at the date of grant. The fair value is expensed on a straight-line basis over the vesting period, with a corresponding increase in equity. This is based upon the company's estimate of the shares or share options that will eventually vest which takes into account all vesting conditions and non-market performance conditions, with adjustments being made where new information indicates the number of shares or share options expected to vest differs from previous estimates. Fair value is determined using an appropriate pricing model. All market conditions and non-vesting conditions are taken into account when estimating the fair value of the shares or share options. As long as all other vesting conditions are satisfied, no adjustment is made irrespective of whether market or non-vesting conditions are met. Where the terms of an equity-settled transaction are modified, an expense is recognised as if the terms had not been modified. In addition, an expense is recognised for any increase in the fair value of the transaction, as measured at the date of modification. Where an equity-settled transaction is cancelled or settled, it is treated as if it had vested on the date of cancellation or settlement, and any expense not yet recognised in profit or loss is expensed immediately. Cash-settled share-based payment transactions are measured at the fair value of the liability. Until the liability is settled, the fair value of the liability is re-measured at each reporting date and at the date of settlement, with any changes in fair value recognised in profit or loss for the period.

4. Employee numbers

The average number of persons employed by the company during the year amounted to 5 (2025: 4 ).

5. Tangible assets

	Office equipment	Software development	Total
	£	£	£
Cost
At 1 May 2025	13,669	1,103,535	1,117,204
Additions	3,683	67,384	71,067
	--------	------------	------------
At 30 April 2026	17,352	1,170,919	1,188,271
	--------	------------	------------
Depreciation
At 1 May 2025	9,031	739,660	748,691
Charge for the year	4,043	56,722	60,765
	--------	------------	------------
At 30 April 2026	13,074	796,382	809,456
	--------	------------	------------
Carrying amount
At 30 April 2026	4,278	374,537	378,815
	--------	------------	------------
At 30 April 2025	4,638	363,875	368,513
	--------	------------	------------

6. Debtors

	2026	2025
	£	£
Trade debtors	178,800	42,000
Other debtors	19,020	48,127
	---------	--------
	197,820	90,127
	---------	--------

7. Creditors: amounts falling due within one year

	2026	2025
	£	£
Bank loans and overdrafts	4,878	4,878
Trade creditors	7,388	132,172
Social security and other taxes	66,283	11,069
Other creditors	379,219	305,688
	---------	---------
	457,768	453,807
	---------	---------

8. Creditors: amounts falling due after more than one year

	2026	2025
	£	£
Bank loans and overdrafts	16,259	21,137
	--------	--------

9. Share-based payments

The model assumes the government gilt rate at the time of issue as the risk-free rate and uses 50% volatility, which is similar to public companies undertaking comparable trades on the same date. The share options have a maximum vesting period of 3 years from the date of grant and become exercisable spread over this period.

Details of the number and weighted average exercise prices (WAEP) of share options during the year are as follows:

	2026		2025
	No.	WAEP	No.	WAEP
Granted during the year	8,417	4.26	–	–
Exercised during the year	( 650)	4.26	–	–
	-------	-----	----	----
Outstanding at 30 April 2026	7,767	4.26	–	–
	-------	-----	----	----

Exercisable at 30 April 2026	7,767	4.26	–	–
	-------	-----	----	----

The total expense recognised in profit or loss for the year is as follows:

	2026	2025
	£	£
Equity-settled share-based payments	5,825	–
	-------	----

The Directors believe the value of the services received is equal to the fair value of the share equity-settled options granted and therefore, is measured at the grant date using the Black-Scholes option pricing model, considering the terms and conditions upon which the instruments were granted.